Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

Egils Vjaters; Martin Bögemann; Neal D. Shore; Matthew R. Smith; Teuvo L. J. Tammela; Albertas Ulys; Sergey Polyakov; Mindaugas Jievaltas; Murilo Luz; Boris Alekseev

doi:10.1016/j.eururo.2022.11.018

Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

Egils Vjaters
, Martin Bögemann
, Neal D. Shore
, Matthew R. Smith
, Teuvo L. J. Tammela
, Albertas Ulys
, Sergey Polyakov
, Mindaugas Jievaltas
, Murilo Luz
, Boris Alekseev

Medicīnas un dzīvības zinātņu fakultāte

Zinātniskās darbības rezultāts: Devums žurnālam › Kļūdu labojums

1 Atsauce (Scopus)

Kopsavilkums

The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

Oriģinālvaloda	Angļu
Lapas (no-līdz)	e60
Žurnāls	European Urology
Sējums	83
Izdevuma numurs	2
DOIs	https://doi.org/10.1016/j.eururo.2022.11.018
Publikācijas statuss	Publicēts - febr. 2023

ANO IAM

Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)

3. IAM — Laba Veselība un Labbūtība

OECD Zinātnes nozare

3. Medicīnas un veselības zinātnes

Piekļuve Dokumentiem

10.1016/j.eururo.2022.11.018

Citi faili un saites

Nospiedums

Uzziniet vairāk par pētniecības tēmām “Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))”. Kopā tie veido unikālu nospiedumu.

Citēt šo

Vjaters, E., Bögemann, M., D. Shore, N., R. Smith, M., L. J. Tammela, T., Ulys, A., Polyakov, S., Jievaltas, M., Luz, M., & Alekseev, B. (2023). Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). European Urology, 83(2), e60. https://doi.org/10.1016/j.eururo.2022.11.018

Vjaters, Egils ; Bögemann, Martin ; D. Shore, Neal u.c. / Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). (gadā): European Urology. 2023 ; Sēj. 83, Nr. 2. lpp. e60.

@article{8071639b8a924b4a912c566843bb771f,

title = "Erratum to {"}Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))",

abstract = "The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.",

author = "Egils Vjaters and Martin B{\"o}gemann and \{D. Shore\}, Neal and \{R. Smith\}, Matthew and \{L. J. Tammela\}, Teuvo and Albertas Ulys and Sergey Polyakov and Mindaugas Jievaltas and Murilo Luz and Boris Alekseev",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2023",

month = feb,

doi = "10.1016/j.eururo.2022.11.018",

language = "English",

volume = "83",

pages = "e60",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

Vjaters, E, Bögemann, M, D. Shore, N, R. Smith, M, L. J. Tammela, T, Ulys, A, Polyakov, S, Jievaltas, M, Luz, M & Alekseev, B 2023, 'Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))', European Urology, sēj. 83, Nr. 2, lpp. e60. https://doi.org/10.1016/j.eururo.2022.11.018

Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). / Vjaters, Egils; Bögemann, Martin; D. Shore, Neal u.c.
(gadā): European Urology, Sēj. 83, Nr. 2, 02.2023, lpp. e60.

Zinātniskās darbības rezultāts: Devums žurnālam › Kļūdu labojums

TY - JOUR

T1 - Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

AU - Vjaters, Egils

AU - Bögemann, Martin

AU - D. Shore, Neal

AU - R. Smith, Matthew

AU - L. J. Tammela, Teuvo

AU - Ulys, Albertas

AU - Polyakov, Sergey

AU - Jievaltas, Mindaugas

AU - Luz, Murilo

AU - Alekseev, Boris

PY - 2023/2

Y1 - 2023/2

N2 - The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

AB - The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

UR - https://www.sciencedirect.com/science/article/pii/S0302283822028378

UR - https://www.scopus.com/pages/publications/85145287074

U2 - 10.1016/j.eururo.2022.11.018

DO - 10.1016/j.eururo.2022.11.018

M3 - Erratum

SN - 0302-2838

VL - 83

SP - e60

JO - European Urology

JF - European Urology

IS - 2

ER -

Vjaters E, Bögemann M, D. Shore N, R. Smith M, L. J. Tammela T, Ulys A u.c. Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). European Urology. 2023 febr.;83(2):e60. doi: 10.1016/j.eururo.2022.11.018